What the FDA labels say about taking them together
Enzalutamide and palbociclib
Palbociclib's FDA label of July 2, 2026 names enzalutamide in its drug interactions section; the enzalutamide labels PlainMeds reads (2) do not name palbociclib. The palbociclib label: “Avoid concomitant use of strong CYP3A inducers.”
Check it at the source: the enzalutamide FDA label on DailyMed (effective July 28, 2026, Astellas Pharma US, Inc.); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the enzalutamide label say about palbociclib?
Enzalutamide's label (effective July 28, 2026) and its 1 other brand-application label do not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Xtandi), Astellas Pharma US, Inc., effective July 28, 2026 (SPL set b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf), via openFDA; the full label on DailyMed
What does the palbociclib label say about enzalutamide?
Palbociclib label, drug interactionsAvoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wort) [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Enzalutamide | Palbociclib | |
|---|---|---|
| Labeled for | Prostate cancer | Breast cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once